Drug details

Fasenra (benralizumab for subcutaneous injection)

type of Interleukin Inhibitors, Monoclonal Antibodies, Anti-asthmatics

Fasenra (benralizumab) injection is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody (IgG1, kappa) indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.

The drug is often used to treat Asthma .

This drug may have the following side effects:

• fever,
• headache,
• sore throat,
• hypersensitivity reactions, and
• injection site reactions (pain, redness, itching, or a small lump)

The following drugs are related to Fasenra, either as a replacement or used together:

• Airduo Digihaler (fluticasone propionate and salmeterol inhalation powder)
• Airsupra (albuterol and budesonide inhalation aerosol, for oral inhalation)
• Albuterol Sulfate Tablets (albuterol sulfate tablets)
• Qvar Redihaler (beclomethasone dipropionate hfa inhalation aerosol)
• Tezspire (tezepelumab-ekko injection, for subcutaneous use)